Medicare spent $26 billion in recent years on dozens of medicines that three other wealthy nations didn't recommend for coverage because they deemed them to be of little value, according to a new study cited by STAT.

The Trump administration is working on an executive order that would lower prices on all branded drugs sold to Medicare Part B and Part D,  according to an exclusive Reuters report. 

In the last two weeks, several hospitals announced plans to implement innovative partnerships, programs or technology to improve pharmacy operations. 

New Jersey-based Celgene will pay $55 million to resolve a class-action suit that accused the drugmaker of blocking generic competition in the cancer market at the expense of patients.

A former sales representative for Sun Pharmaceuticals filed a retaliation lawsuit against the drugmaker, claiming he was fired for complaining about its marketing tactics, according to STAT news. 

Jubilant Cadista Pharmaceuticals, a drugmaker based in Maryland, is recalling one lot of its  drospirenone and ethinyl estradiol birth control tablets over concerns that they might not work properly, the company said this week.

In an effort to better address the social aspects of health, CVS Health is launching a network to help connect Aetna's most vulnerable patients to support services in their communities.

A Veterans Affairs pharmacy in North Charleston, S.C., received the largest amount of opioid pills of all pharmacies nationwide between 2006 and 2012, according to Drug Enforcement Administration data published by The Washington Post.

The FDA has approved Hadlima, a biosimilar to AbbVie's blockbuster rheumatoid arthritis treatment Humira. However, it won't be available in the U.S. until June 2023.

The FDA has approved Pfizer's biosimilar to Rituxan, a treatment for some cancers and autoimmune diseases.